pre|CISION® Platform · FAP-Targeted Oncology · Investment Analysis
Avacta Therapeutics (AIM: AVCT) is a UK-headquartered, clinical-stage biopharmaceutical company, founded in 2003 and listed on London's AIM market. Based at Imperial College's White City campus in London with US operations in Philadelphia, Avacta has completed a decisive strategic transformation: divesting its diagnostics businesses (Launch Diagnostics sold for £12.9m in April 2025; Coris BioConcept SRL sold for £2.15m) to become a pure-play precision oncology company.
The core asset is the proprietary pre|CISION® platform — a tumour-activated drug delivery system exploiting fibroblast activation protein (FAP), a protease that is highly overexpressed in the tumour microenvironment (TME) of most solid cancers, but virtually absent in healthy adult tissue. pre|CISION® peptide drug conjugates (PDCs) and Affimer drug conjugates (AffDCs) are designed to remain inert in circulation and release their cytotoxic payload specifically within the tumour, dramatically reducing systemic toxicity and enabling the use of far more potent chemotherapy than would otherwise be tolerable.
The company has approximately 457.9 million shares in issue, a current market capitalisation of roughly £408 million, and a management team led by CEO Dr. Christina Coughlin (oncology drug development veteran, named In Vivo 2026 Rising Leader — one of 30 selected globally by Citeline's editorial board from across biopharma, medtech and diagnostics) and CFO Brian Hahn, bolstered by recently appointed chief scientific officer Dr. Francis Wilson and two new non-executive directors in 2024/25.
Avacta has developed a differentiated, tumour-agnostic drug delivery platform that clinically validates the pre|CISION® mechanism of action (proven in humans via AVA6000), can be applied to many payloads and tumour types (FAP is expressed in ~90% of solid tumours), and is cheaper to manufacture than antibody-based ADCs. With two assets now in the clinic, a third-generation dual-payload program in preclinical development, and active partnership discussions with multiple large pharma companies across all three generations, the company sits at an inflection point — yet trades at a fraction of comparable platform companies that have secured big-pharma deals. CEO Christina Coughlin confirmed in April 2026: "Our first, second and third generation assets are all attracting substantial interest from multiple parties for potential partnering." The FOCUS-01 Phase 1 trial of AVA6103 is designed to recruit 144 patients across 7 indications — a size that signals intent to generate robust efficacy data, not merely safety signals.
Fibroblast Activation Protein-alpha (FAP) is a type II transmembrane serine protease expressed almost exclusively by cancer-associated fibroblasts (CAFs) in the tumour stroma — the scaffolding that surrounds most solid tumours. Crucially, FAP is virtually absent in normal adult tissues, making it an exceptionally selective tumour target. Research confirms FAP upregulation across over 90% of epithelial solid tumours, including breast, colorectal, pancreatic, lung, brain, ovarian, salivary gland, cervical, and gastric cancers. This pan-tumour expression is the foundational reason why Avacta's platform is potentially transformative.
pre|CISION® PDCs consist of a potent cytotoxic payload covalently linked to a proprietary peptide sequence that is selectively cleaved by FAP enzyme activity in the TME. The peptide acts as a "molecular lock" preventing cellular entry and activation until FAP releases the payload. Clinical pharmacokinetic data from the AVA6000 Phase 1a trial have confirmed the platform mechanism through direct tumour biopsy measurement in humans. Tumour biopsies taken 24 hours post-dose showed a mean doxorubicin concentration of 860 ng/gm in tumour tissue (range 76–2,310 ng/gm, n=11) versus 8.3 ng/ml free doxorubicin in simultaneous blood samples — a ratio of approximately 100:1 at the mean, rising to 278:1 at the upper range, versus a 1:1 ratio for conventional doxorubicin. This is directly measured drug concentration in human cancer tissue — not a model, not a calculation. A critical additional finding from the ESMO 2024 biopsy data: FAP expression level in the tumour does not correlate with doxorubicin concentration in the TME — confirming that even patients with moderate or low FAP expression achieve high tumour drug concentrations. Published in the Annals of Oncology. This is the mechanistic foundation that makes every subsequent programme de-risked.
Avacta's proprietary Affimer proteins are antibody mimetics — small, highly stable scaffold proteins that can be engineered to bind specific targets with high affinity. Unlike antibodies, they are synthetically produced, have lower manufacturing costs, smaller size (enabling better tumour penetration), and can be engineered for targets that are difficult to access with antibodies (such as GPCRs). In the Gen 3 AffDC format, the Affimer serves as the targeting moiety, carrying both the FAP-cleavable linker and the payload, combining tumour-specific targeting with tumour-specific release.
Preclinical head-to-head data presented in Q1 2026 demonstrated that AVA6103's sustained-release pre|CISION® delivery achieved a three-fold higher tumour selectivity index compared to a leading marketed antibody drug conjugate (not named, but broadly understood to reference a topo I-based ADC in the class of Enhertu/T-DXd). This comparative data significantly strengthens the investment case, as it positions Avacta's smaller-molecule approach as potentially superior in tumour penetration and selectivity to the current gold-standard ADC platform. The data will be presented at AACR Annual Congress in San Diego on 21 April 2026.
AVA6000 is the most mature asset and provides the critical proof-of-concept for the entire platform. Key findings from the combined Phase 1a (n=11) and Phase 1b (n=19 evaluable) cohorts in salivary gland cancer as of December 2025:
Not a surrogate marker, not a model prediction, not an inference from plasma PK. Directly measured drug concentration in human cancer tissue taken from living patients. Published in the Annals of Oncology.
⚡ ASCO 2026 CONFIRMED. AVA6000 Phase 1a/1b data will be presented at ASCO Annual Meeting, Chicago, 30 May–3 June 2026. Abstract title already published: "A phase Ia/Ib trial of FAP-Dox (AVA6000)... and activity against salivary gland cancers." Full abstracts release: 21 May 2026 at 5pm ET. The title is a deliberate efficacy signal — "activity" is not used in ASCO titles for safety-only readouts. Combined 1a/1b dataset (~40-50 SGC patients) with mature follow-up. First public TNBC and STS cohort data. Phase 1b enrolled in first and second line setting — commercially relevant patients, not just heavily pre-treated. The company has stated Phase 2 is planned subject to partner.
AVA6103 carries the pre|CISION® peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development — the same drug class as the blockbuster Enhertu (trastuzumab deruxtecan) payload. The Gen 2 sustained-release mechanism is more specific than a simple slow-release linker: the capping group contains a moiety that enhances FAP active site binding, trapping the conjugate in the FAP active site for longer periods and delivering sustained release of exatecan directly in the TME over five or more days, while conventional exatecan disappears from the tumour within hours. Complete tumour responses have been observed in preclinical patient-derived cancer models with just three doses, even in low-FAP settings. The FOCUS-01 trial is designed to recruit 144 patients total across 7 indications — approximately 20 per cohort — a size that signals intent to generate robust efficacy signals, not merely safety data. Initial Phase 1 data is anticipated in late H2 2026 — a major potential value inflection point.
The full poster PDF published on the Avacta website reveals precise quantitative data that substantially extends the RNS. Four findings not previously public:
Three new FOCUS-01 cohorts formally added based on Tempus LENS biomarker data:
Total FOCUS-01 indication reach: 7 cancer types. Combined with AVA6000's 3 indications: 10 cancer types across the platform.
Cash at 31 December 2025: £16.9 million
Following oversubscribed £10 million placing in March 2026 (at 63p, 9.35% discount), runway is extended to early Q1 2027.
Total equity raised in 2025: £22.5 million. Zeus Capital acted as sole bookrunner for the March 2026 raise (oversubscribed — a positive signal of institutional demand).
Avacta has a Heights Capital convertible bond with £19.2M principal remaining (13 May 2026, after £1.2M converted into 1,604,063 shares at 74.8p). Quarterly repayments due January and April 2026 deferred until October 2027. Conversion price: 75p. Heights is voluntarily converting at 75p while the market price is 82.5p — banking ~9% spread per tranche. Maximum remaining dilution: ~25.6M shares (5.6% of register) if entire £19.2M converts at 75p. Each quarterly tranche: ~1.6M shares (0.35% dilution). October 2027 maturity cliff: all unconverted principal due simultaneously — eliminated if partnership deal closes in 2026/7. See full bond analysis card above.
Revenue was negligible in 2024 (£113k, down 96% following diagnostics divestment). Losses were £52.8m in 2024. The company is pre-revenue therapeutics and will remain so until a licensing deal or Phase 2 commercialisation.
The company's pure-play therapeutics status means its financial position is simple: it spends cash on R&D and raises equity periodically to fund milestones. The oversubscribed nature of recent raises (both the October 2025 £16m and March 2026 £10m) is a positive market signal, indicating continued institutional support. The company has stated that the current runway extends beyond multiple value inflection points through the rest of 2026 — specifically the AVA6000 H1 data update and the initial AVA6103 Phase 1 data in H2.
Cash burn is estimated at approximately £20–25 million per annum based on recent results, consistent with running two clinical-stage programmes simultaneously. A partnership deal on AVA6000 (which management is actively pursuing) would likely include an upfront payment that could substantially extend runway and reduce dilution risk. A NASDAQ dual listing is a confirmed corporate objective, explicitly stated in the March 2026 corporate deck — this would dramatically broaden the US institutional investor base and is a well-established re-rating catalyst for UK biotech companies.
The bear case for Avacta rests almost entirely on financing risk — serial equity dilution as the company burns ~£25M/yr towards clinical milestones. However the market is failing to price a significant alternative that Avacta's board composition makes unusually accessible: royalty-based financing. This is non-dilutive, non-debt capital in exchange for a defined share of future product revenues, and it has become the dominant alternative financing mechanism for clinical-stage biotechs in the 2023–2026 period.
David Bryant, appointed NED in May 2025, is currently an active Advisor to Healthcare Royalty (HCRx) — the world's largest specialist biopharma royalty acquisition firm, now majority-owned by KKR since July 2025 with $7bn+ committed across 110+ products. Bryant was simultaneously appointed to Avacta's board and holds an active advisory relationship with the most obvious royalty financing counterparty. This is not coincidental. Companies do not appoint advisors to their board without a strategic rationale, and that rationale here is transparent: Bryant brings both commercial pharma expertise (GSK, Pfizer, Clinigen) and a direct warm channel into HCRx's deal team.
Royalty financing comes in two main structures — both applicable to Avacta:
There are three potential royalty financing trigger points for Avacta, each with different sizing potential:
The market is pricing Avacta as if serial equity dilution is the only financing path available. The board composition — an active HCRx advisor, a CFO who has raised $700M+ and sits on BIO's Finance Committee, and the founder of Zeus Capital as bookrunner — suggests a more sophisticated financing toolkit is already being assembled. Royalty financing doesn't eliminate dilution risk entirely, but it changes the probability distribution dramatically. The bear case becomes considerably less bearish if non-dilutive capital of £30–80M is accessible in the near term.
Avacta's platform is not confined to a single indication — it is a tumour-agnostic drug delivery system applicable to any solid cancer expressing FAP, which is upregulated in ~90% of epithelial solid tumours. This analysis models realistic peak revenue potential for each indication, incorporating two unique structural revenue uplifts: (1) more patients eligible to be dosed — because pre|CISION® dramatically reduces cardiac and haematologic toxicity, patients excluded from conventional doxorubicin can now be treated; and (2) longer treatment duration — the FDA's removal of the lifetime maximum doxorubicin dose cap in early 2026 means responding patients can continue therapy indefinitely, extending per-patient revenue. All figures represent peak annual global revenues at full commercialisation (estimated 2032–2038).
pre|CISION® PDCs are small molecule drugs with ADC-like targeting properties but manufactured via shorter chemical synthesis — a material cost advantage over biologic ADC manufacturing that could underpin superior commercial margins in a licensed partnership.
The bear/base/bull scenarios below use royalty rates as a proxy for simplicity, but the true bull case is a mixed ownership model reflecting Avacta's likely real-world commercialisation strategy: retain and self-commercialise small indications, partner large ones for upfront cash plus royalties, and potentially out-license platform access in specific geographies.
The royalty rates used in individual indication cards (8% bear / 12% base / 20% bull) are simplifications. The true bull scenario replaces the 20% royalty on SGC with ~65% net margin ownership economics — shown separately in the valuation section. Upfront deal payments are not modelled in the per-indication revenue figures but are captured in the M&A comparable valuation framework.
The lead indication with the clearest path to approval. No approved chemotherapy standard of care in metastatic SGC makes AVA6000 a potential first-in-class 1L agent — capturing the full eligible population rather than a 2L+ slice. Orphan Drug Designation would deliver 7-year US market exclusivity and accelerated FDA review.
Key uplifts: No lifetime cap means indefinite treatment for responders (currently 6+ patients from the Phase 1b still on therapy). Cardiac-excluded patients (~40% of otherwise-eligible SGC population) re-enabled — FAP-Dox delivered with no MTD even at 4× conventional dox dose.
Avacta's largest commercial opportunity for AVA6000. Conventional doxorubicin is a foundational chemotherapy backbone for TNBC, but its use is severely limited by cumulative cardiac toxicity — forcing oncologists to use it sparingly and halting therapy in responding patients. FAP-Dox directly resolves this: it delivers full-dose anthracycline efficacy without the cardiac ceiling. FAP is strongly expressed in TNBC stroma.
Key uplifts: An estimated 30–40% of TNBC patients are currently excluded from doxorubicin due to cardiac contraindications — FAP-Dox re-opens treatment for this group. Removal of lifetime cap converts short courses into long-duration chronic therapy, potentially extending average treatment from 6 cycles to 12+. Possible combination with pembrolizumab (Keytruda) — which alone generates ~$2bn in TNBC revenue — could create a blockbuster combination.
The most direct clinical application of FAP-Dox: doxorubicin has been the standard 1L treatment for advanced STS for over 40 years and the main limitation is always the cardiac toxicity ceiling. AVA6000 resolves this directly. The global STS drug market was $2.8bn in the 7MM in 2024, growing at 10.4% CAGR. FAP is widely expressed across the full STS histological spectrum (50+ subtypes), meaning AVA6000 is applicable broadly rather than to selected subtypes.
Key uplifts: STS frequently affects younger adults (<50), who are at highest risk from dox cardiotoxicity — AVA6000's profile directly benefits this demographic. Responding patients who currently have to stop treatment due to cumulative dose limits can now continue indefinitely — directly extending progression-free survival and per-patient revenue.
PDAC has among the highest FAP expression of any solid tumour — the dense desmoplastic stroma surrounding pancreatic tumours is abundant in FAP-expressing cancer-associated fibroblasts. This is the same stroma that makes PDAC so resistant to conventional systemic therapies. AVA6103's sustained-release mechanism holds exatecan in the TME for 5+ days, enabling deeper penetration of this notoriously impermeable stroma. Exatecan itself is 100–1,000× more potent than irinotecan (SN-38), the current topo I inhibitor used in PDAC (Onivyde).
The global pancreatic cancer treatment market was ~$3.8bn in 2025 and is projected to reach $10–14bn by 2034 (12–16% CAGR), driven by desperate unmet need. AVA6103 would enter as a first-in-class exatecan agent for PDAC — pricing power ~$160–200k/yr comparable to ADC-class topo I inhibitors.
SCLC is highly sensitive to topoisomerase I inhibitors — irinotecan and topotecan are current standard 2L therapies. Exatecan is dramatically more potent than either, and AVA6103's sustained-release pre|CISION® delivery concentrates it within the tumour while sparing normal tissue — enabling the potency to be exploited safely. The SCLC market was $3.7–4.5bn in 2024, and the FDA approval of tarlatamab (2024) demonstrates that highly potent novel agents can achieve rapid market uptake in this indication.
SCLC patients frequently present with poor performance status — AVA6103's reduced systemic toxicity enables treatment of patients who would currently be deemed too frail for conventional chemotherapy, expanding the addressable population meaningfully.
Gastric cancer has a much larger global incidence than US figures suggest — over 1 million new cases per year worldwide, predominantly in East Asia. Avacta has existing relationships with Daewoong Pharmaceutical (South Korea) and other Asian partners from the diagnostics era, potentially giving early access to the large Asian market. The Tempus AI collaboration has confirmed high FAP expression in gastric cancer tissue samples.
Exatecan class has demonstrated promise in gastric cancer contexts, and FAP-targeted delivery could improve the therapeutic window significantly vs. irinotecan-based regimens. Global market estimated at $3–5bn in 2025 with a large and growing Asian patient population.
The cervical cancer market is larger than most realise at $8.65bn globally (2024), driven by 660,000 annual cases worldwide. Keytruda has transformed the first-line metastatic setting, creating a substantial 2L+ unmet need for patients who progress on pembrolizumab-based regimens. FAP expression in cervical cancer stroma is confirmed in Avacta's Tempus AI database analysis.
Cervical cancer frequently affects younger women — reduced toxicity is especially important for quality-of-life preservation in this demographic. A differentiated, lower-toxicity topo I inhibitor targeting the FAP-rich tumour stroma fills a genuine clinical gap in the post-Keytruda treatment landscape.
Once AVA6000 receives its first approval — most likely accelerated approval in SGC — every oncologist in every country where the drug is approved can legally prescribe it off-label for any other indication. This is not theoretical: 50–75% of all oncology drug use in the US is already off-label. The question is how large this opportunity is and what gates it.
Hormone receptor-positive breast cancer (HR-BC, also called luminal breast cancer) is by far the most common breast cancer subtype, accounting for approximately 70–75% of all breast cancer diagnoses — roughly 290,000 cases in the US alone and over 1.5 million globally per year. While endocrine therapy is the backbone of treatment, patients with advanced or metastatic HR-BC who progress through multiple lines become candidates for chemotherapy including topo I inhibitors. Trodelvy (sacituzumab govitecan) already generates multi-billion dollar revenues in this space — AVA6103's superior tumour selectivity and sustained-release profile could offer a meaningful differentiated option in 2L+ post-CDK4/6 inhibitor disease.
The global breast cancer therapeutics market exceeds $25bn. The inclusion of HR-BC in AVA6103 expansion cohorts — disclosed the same day as AACR — is the single most commercially significant pipeline update Avacta has made. It transforms AVA6103 from a specialist oncology drug into a potential mainstream breast cancer treatment. FAP is expressed in the stromal compartment of HR-BC tumours.
Non-small cell lung cancer is the largest single cancer drug market globally at ~$22 billion, growing at ~12% CAGR. NSCLC comprises approximately 85% of all lung cancers and represents a treatment landscape dominated by targeted therapies (EGFR/ALK inhibitors, Tagrisso) and immunotherapy (Keytruda), but with significant unmet need in patients who have progressed through these agents. Topo I inhibitors are increasingly being explored in NSCLC — Datroway (datopotamab deruxtecan) received FDA approval for NSCLC in June 2025, validating the payload class in this indication. AVA6103's FAP-activated delivery of a more potent exatecan payload could differentiate itself through superior safety versus ADC-class competitors.
Combined with SCLC already in the trial, Avacta now has complete lung cancer coverage across both major subtypes — a compelling commercial narrative for any pharma partner with lung oncology assets.
Colorectal cancer is one of the top three cancers globally by incidence, with approximately 150,000 new cases per year in the US and 1.9 million globally. The CRC drug market is substantial and growing. FAP is strongly expressed in the desmoplastic stromal tissue surrounding colorectal tumours — data from the original AVA6000 Phase 1a trial enrolled colorectal cancer patients in the FAPmid category, already establishing clinical precedent. The Tempus AI collaboration has further confirmed FAP expression patterns across colorectal cancer tissue.
The CRC expansion also directly intersects with the oral delivery thesis explored in the hidden signals section. FAP-expressing colorectal tumour stroma is directly accessible via the gastrointestinal tract — an orally administered pre|CISION® drug would not need systemic bioavailability to reach the FAP enzyme in colonic tumour stroma. This makes CRC the most scientifically compelling indication for a future oral formulation. Crucially, topo I inhibitors (irinotecan, as Onivyde) are already standard-of-care in colorectal cancer — AVA6103 with its more potent exatecan payload could offer a superior profile.
Note: Peak revenues modelled at full commercialisation (est. 2032–2038). Bear/base/bull Avacta share uses royalty proxy of 8%/12%/20%. These understate the true bull case — see below.
A 20% royalty applied uniformly across all 10 indications materially understates the bull scenario. The realistic high-end outcome is a mixed structure where Avacta retains full ownership of manageable indications and partners mainstream ones at higher royalty rates than a typical unvalidated platform would command, plus large upfront payments:
The total indication-level peak revenues across all partners range from $3.9bn to $9.4bn annually. The gap between these and Avacta's share reflects the value captured by pharmaceutical partners — which is exactly why the acquisition logic is so powerful. At 2–4× peak revenues as a one-time transaction multiple (consistent with comparable platform deals), an outright acquisition of Avacta could command $2–3bn floor, $5–10bn+ bull case — versus the current ~£408M market cap.
Following full review of all data in this report, all valuation scenarios have been revised upward. Seven specific factors justify the upgrade — none require new clinical data:
Applying conservative P/S multiples (3–5×) to Avacta's risk-adjusted share of peak revenues — reflecting the probability of clinical and commercial success — gives a range of implied valuations. We use a 40% probability-of-success (PoS) weighting for AVA6103 at Phase 1 stage — revised upward from the standard industry 25% to reflect that the delivery mechanism is already clinically validated in 63 humans (AVA6000), the payload (exatecan) is a known cytotoxic, and the AACR poster confirmed activity even in very low FAP tumours. The residual clinical risk is linker PK optimisation, not mechanism proof. Standard 25% PoS applies to novel drugs where mechanism is unproven; it materially overstates risk for a validated platform programme. PoS rises to 60% post strong Phase 2 data.
Using a standard oncology rNPV approach: Phase 1 PoS ~25% per indication → Phase 2 PoS ~50% → Phase 3/approval PoS ~65%. Applying an 8% discount rate and 10-year NPV horizon to Avacta's base-case royalty share of $465M–$1.13bn peak annual revenues:
The most instructive comparables are Synaffix → AbbVie (~$1.2bn) — pure ADC linker IP, zero clinical assets — and Gilead/Tubulis ($5bn) — two pre-clinical ADC assets, no human proof-of-concept. Avacta has: clinical validation in 63 humans, 10 indications across two drugs, Gen 3 dual-payload data, STING patent, and prostate cancer as an unmodelled indication. Paying less than Synaffix for Avacta's entire platform would be irrational. The correct framing is not "Tubulis minus a discount" — it is "Tubulis plus a substantial premium for clinical validation, breadth, and defensive value." See full competitive acquisition analysis below.
In a competitive auction, Avacta's acquisition price is determined not by fundamental value alone but by the intersection of strategic necessity, competitive threat, and auction dynamics. The presence of AstraZeneca/Daiichi Sankyo in any auction changes the pricing model entirely.
Important update — May 2026: Daiichi Sankyo's five-year 2030 business plan makes no mention of FAP-targeted approaches. Their strategy is explicitly built on maximising DXd ADC value through antigen-targeted delivery (HER2, TROP2, HER3, B7-H3, CDH6) across 20+ indications, with next-generation BGTs focusing on multi-specific antibodies, targeted protein degradation and siRNA. DSC's internal view is that biomarker selection captures the payload-delivery opportunity adequately. This weakens but does not eliminate the defensive acquisition argument for the combined AZ/DSC entity.
AstraZeneca specifically retains a separate strategic logic independent of DSC's roadmap. AZ's interest is in extending the commercial life of the deruxtecan payload franchise beyond Enhertu's patent expiry in the mid-2030s. A FAP-targeted delivery mechanism that works in antigen-low patients (who don't respond to antibody-targeted ADCs) and in second/third line after Enhertu progression could extend the DXd payload commercial runway significantly. AZ and DSC have divergent interests here: DSC owns the antibody-linker technology and benefits from antibody targeting; AZ benefits from extending the payload's reach regardless of delivery mechanism.
Novartis already holds exclusive worldwide rights to FAPI-46 and FAPI-74 — FAP-targeting radioligand agents. They have invested in FAP biology and understand the target deeply. Avacta's pre|CISION® is complementary not competitive to their radioligand approach: FAP-PDC delivers small-molecule cytotoxics through enzyme cleavage while FAPI delivers radiation. Combined, Novartis would own a fully integrated FAP oncology franchise: image with FAPI-PET, treat with pre|CISION® PDC, ablate with FAP radioligand. This is the most compelling integrated oncology platform story in the solid tumour space.
Paid $5bn for Tubulis in December 2024 — two pre-clinical ADC assets, no human data. Avacta has everything Tubulis had plus clinical validation in 63 humans plus 8 additional indications plus Gen 3 data. If Gilead's BD team is rational, Avacta is worth materially more than they paid for Tubulis. Their oncology franchise (Trodelvy/TROP2, Yescarta/CAR-T) has major gaps in solid tumours that pre|CISION® fills. Their Tubulis acquisition explicitly confirms they want platform assets, not single drugs.
Dedicates 40%+ of annual R&D to oncology following $43bn Seagen acquisition. Specifically pursuing "novel targets and improved, differentiated payloads" and "next-gen payloads to improve selectivity, potency, therapeutic index." Has sigvotatug vedotin (exatecan ADC) in late-stage NSCLC — AVA6103's FAP-Exd would complement by reaching FAP-low patients their antibody ADC misses. Spent $9bn on M&A in 2025 alone. An Avacta acquisition at £800M-£2bn would be a rounding error on their balance sheet.
Most sophisticated understanding of tumour microenvironment biology of any major pharma. Has run multiple internal FAP-targeted programmes that have not reached the clinic. Avacta hands them a clinically validated FAP mechanism with two drugs in the clinic and a STING patent on the platform. The STING angle is particularly relevant — Roche's PD-L1 franchise (Tecentriq/atezolizumab) is losing share to Keytruda; a FAP-STING PDC that converts cold tumours to hot ones would reinvigorate their immuno-oncology competitive position. Roche paid $4.3bn for Foundation Medicine (diagnostics only) and $4.8bn for Spark Therapeutics (gene therapy platform). A clinically validated tumour delivery platform applicable to 90% of solid tumours is strategically more valuable than either of those.
Note: A single-bidder negotiated deal at £800M–£1.5bn would almost certainly be rejected by the board and institutional shareholders. Chilton sold Clinigen for £1.3bn and knows what leaving value on the table looks like. Goldberg has been on boards for two acquisitions at $3bn and $8.4bn. Hughes has Apax Partners M&A experience. Hahn has fiduciary duty to maximise shareholder value. Under UK Takeover Code, once an approach is public, the board must consider all potential offerors. Institutional shareholders who understand the platform would challenge any recommendation below £2–3bn. The realistic minimum for board recommendation is £2bn+.
The current share price of 89p represents a market that is pricing in significant clinical and partnership risk — appropriately so for a pre-revenue Phase 1 company. The base-case rNPV and peer comparables both suggest the stock is materially undervalued on a probability-weighted basis relative to the pipeline's true potential, provided clinical data continues to support the platform thesis. Valuations revised upward from initial estimates to reflect: expanded addressable population from low-FAP activity, off-label doxorubicin market ($500M–$2bn unmodelled), prostate cancer as potential additional indication, platform-calibrated PoS of 40% vs standard 25%, and NASDAQ listing premium. The key watch-point remains the H2 2026 AVA6103 Phase 1 readout, which will either substantially de-risk the investment case or reset expectations downward.
AVCT's share price has been highly volatile over the past few years, consistent with a pre-revenue clinical-stage biotech on AIM. The stock experienced a dramatic multi-year downtrend from peaks well above 200p (during 2020–21 biotech/COVID boom), reaching a trough of approximately 26p in late 2024/early 2025 as sentiment deteriorated, diagnostics divestments created uncertainty, and cash burn concerns mounted.
26p LOW → 89p HIGH (52-week, 13 May 2026) · Current: 89p BREAKOUT · Green bars = catalyst events
The 89p close on 13 May 2026 is a technically significant event for three specific reasons:
Note: Stockopedia continues to classify AVCT as a "Momentum Trap" — a label generated from historical price patterns. This classification is algorithmically backward-looking and does not reflect the fundamental step-change in the investment thesis since the AACR data, Science Day, and ASCO confirmation. The classification is likely to upgrade if the stock maintains above 85p for a sustained period and if the ASCO data drives a broker target revision cycle.
Avacta is covered by a small but growing number of sell-side analysts, consistent with its AIM listing. Zeus Capital acts as sole broker and bookrunner. Wider analyst coverage includes firms producing targets in the range below.
TipRanks' AI analyst rates AVCT as Neutral, noting that while clinical progress is genuine, financial constraints (negative EPS, no revenue, convertible bond) and lack of confirmed partnerships represent significant risks. The stock's valuation is described as unattractive on a purely financial basis — which is standard for pre-revenue clinical-stage biotechs and should be viewed through the lens of pipeline value, not traditional fundamental metrics.
"Our first, second and third generation assets are all attracting substantial interest from multiple parties for potential partnering. With our recent financing completed, we now have funding in place beyond multiple value inflection points through the rest of 2026 and we are excited about this potentially transformative period for the Company." — Dr. Christina Coughlin, CEO of Avacta, Q1 2026 Business Update (April 2026)
"These data highlight the transformative potential of our pre|CISION® peptide drug conjugates in expanding the efficacy of highly potent therapeutics and support our growing optimism in this program." — Dr. Christina Coughlin, CEO, on AVA6000 Phase 1b SGC data (December 2025)
"It is important to note the high degree of unmet need in this disease where few agents have shown efficacy. I am happy to participate in the trials of AVA6000 in this disease setting in the future." — Dr. Alan Ho, MD PhD, Chief of Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center (Avacta Scientific Advisory Board)
Retail investor commentary on platforms including ADVFN, LSE.co.uk and ShareTalk is broadly constructive, with a vocal bull case centred on the platform comparison argument (Tubulis/$5bn Gilead deal; Avacta at £408M "is a joke" for a clinically validated platform with 10 indications, human biopsy proof, and ASCO abstract confirming SGC activity). The most sophisticated retail commentary focuses on: (1) the sheer breadth of FAP-positive cancer coverage making Avacta's addressable universe far larger than single-drug biotechs; (2) the cost advantage of PDC vs. ADC manufacturing; and (3) the inevitability of big-pharma attention once Phase 1 data on the exatecan program becomes available. Critics point to dilution risk from repeated equity issuance, the convertible bond, and the long road to a partnership deal.
The sentiment asymmetry is notable: bears tend to focus on near-term financial risks and timelines; bulls focus on the enormous long-term platform value that they argue is not reflected in the current market cap.
Avacta competes in the fast-evolving drug conjugate space, where ADC giants (AstraZeneca/Daiichi Sankyo's Enhertu, Pfizer/Seagen) dominate revenues, but a wave of innovative next-generation platforms is attracting unprecedented M&A interest.
Traditional ADCs (like Enhertu, Trodelvy) rely on monoclonal antibody targeting of tumour-surface antigens — which are heterogeneously expressed and require costly biologic manufacturing. Avacta's key advantages over this paradigm:
Universal tumour target — FAP in the stroma rather than heterogeneous surface antigens; works even with low FAP expression via bystander effect. AVA6103 shows preclinical activity even in FAP-low settings.
Manufacturing advantage — Small molecule PDCs vs. large biologic ADC molecules. Significantly simpler and cheaper to produce at scale, potentially enabling better commercial margins.
Platform versatility — Multiple payloads (dox, exatecan, dual) and multiple targeting modalities (PDC, AffDC). Not a single-drug bet.
Direct human tumour biopsy proof — Mean 860 ng/gm doxorubicin in tumour vs 8.3 ng/ml in plasma (100–278:1). FAP expression does not correlate with tumour concentration — mechanism confirmed in human tissue even at low FAP. Published Annals of Oncology.
Conventional biotech risk models apply ~25–30% probability of success from Phase 1 to approval because most drugs fail for one of three reasons: the mechanism of action doesn't work in humans, the safety profile is unacceptable, or the drug doesn't reach the target at therapeutic concentrations. For Avacta, all three of those failure modes have been substantially de-risked by existing clinical data:
The key nuance: The remaining clinical risk is real but qualitatively different from a conventional Phase 1. It is no longer "will this concept work in humans" — that is proven. It is "will the specific kinetics of each successive linker/payload combination be optimised in the clinic?" That is a chemistry and dosing question, not a mechanism question. The probability of success for each successive pre|CISION® programme is higher than the previous one, not the same or lower as standard biotech risk models would assume. The market is not yet pricing this compounding de-risk correctly.
Beyond the publicly disclosed pipeline, a careful reading of personnel backgrounds, patent filings, company language, and structural decisions reveals a set of signals pointing toward platform developments that have not yet been announced. This section assembles those clues — some circumstantial, some surprisingly concrete — and assesses their potential commercial value if realised.
DELIVERED — 6 May 2026. The Science Day at the Royal Society of Chemistry, Burlington House, London was held as planned. Two formal RNS announcements were released on the morning of the event. Key deliverables: (1) Datroway comparison added — TSI ≥3× vs both Enhertu AND Datroway (TROP2-targeted); (2) Tmax quantified at minutes vs >24hrs for both ADCs; (3) AVA6207 durability data updated — prolonged complete responses where Enhertu causes tumour regrowth; (4) peer-reviewed journal publication planned for comparison data. CEO stated IP pace "exceeds industry norms." No new programme, partnership deal, or NASDAQ update disclosed.
Francis Wilson held the role of Director of Chemistry at Summit Therapeutics from 2007 to 2022, where he led multiple programmes from discovery into clinical development. At Summit, his primary work was on ridinilazole — an orally administered small molecule antibiotic specifically designed to concentrate activity within the gastrointestinal tract while sparing systemic circulation. The drug achieved Phase 2 superiority over vancomycin precisely because of its ability to act locally at the site of disease without systemic spread.
The conceptual parallel to pre|CISION® is striking: ridinilazole was engineered to be locally active at a specific biological site, inert elsewhere. This is precisely the intellectual framework underlying FAP-activated payload release. Wilson has spent his entire career solving variations of the same fundamental chemistry problem — site-specific activation — and now leads the team designing the next generation of pre|CISION® IP. His own appointment statement confirms: "We will continue to develop novel intellectual property around our highly successful pre|CISION® platform."
Ellen Watts is a Principal Medicinal Chemist at Avacta Therapeutics working on peptide drug conjugates using the pre|CISION® platform. Previously she was a Senior Scientist at BenevolentAI working on neuro and inflammatory projects, and prior to that completed a PostDoc at the Medicines Discovery Institute, Cardiff University and a PhD in Medicinal Chemistry at The Institute of Cancer Research working on the design and synthesis of novel cancer therapeutics. She also held an industrial placement as a medicinal chemist at Eisai Ltd.
Her BenevolentAI background is particularly interesting. BenevolentAI applies machine learning and AI to drug discovery — exactly the kind of computational approach that could be used to identify novel peptide sequences for new FAP-cleavable linkers with modified properties, including potentially oral bioavailability profiles. Her AACR 2026 authorship (Ellen Watts is listed as an author on the AVA6103 preclinical data presentation at AACR 2026) confirms she is actively involved in the frontline chemistry work. The combination of her AI-assisted drug design expertise from BenevolentAI and classical medicinal chemistry from the ICR and Eisai makes her exactly the kind of scientist who would be working on next-generation platform modifications.
Avacta filed a patent (US20230390409A1) describing a therapeutic conjugate designed to improve efficacy by extending circulating serum half-life in vivo. The conjugate consists of a therapeutic moiety linked through a FAPα-cleavable linker to a half-life extension moiety. The half-life extension moiety can include serum proteins like fibronectin, transferrin, or human serum albumin, or molecules that bind to serum proteins, such as antibodies or non-antibody molecules like affibodies or Affimers.
This patent, co-filed with Tufts University, is particularly significant. The albumin-binding half-life extension mechanism is directly related to the sustained-release architecture already deployed in AVA6103 and AVA7100. But the patent goes further — the therapeutic conjugate produces a concentration of free therapeutic moiety in target FAP-expressing tissue for a period of at least 10, 24, 48, 72, 96, or 120 hours. That 120-hour (5-day) sustained release concept is the same breakthrough already referenced in the AVA6103 program — meaning this patent is the IP foundation for an entire generation of drugs. And critically, the patent claims describe a STING agonist as one of the potential therapeutic moieties — an immunotherapy payload that has been separately challenging to deliver systemically but would be transformative if targetable to the TME via FAP.
A 2025 published clinical study in Clinical Cancer Research examining STING agonists in solid tumours includes a disclosure list that names Avacta Therapeutics among companies with whom the lead investigator (Stéphane Champiat, formerly of Institut Gustave Roussy, now MD Anderson) declares personal fees and outside support. This is not a formal announced partnership — it is a financial disclosure in a peer-reviewed academic paper. But it reveals that Avacta has had a commercial relationship with at least one leading STING agonist clinical researcher that has not been publicly announced.
Cross-referenced with the half-life extension patent that explicitly includes STING agonists as a claimable payload class, this suggests Avacta's interest in STING agonist delivery is not merely theoretical — it appears to involve active scientific engagement with clinical researchers in the field.
Avacta presented preclinical data describing the novel pre|CISION® proteasome inhibitor, AVA3996, at the 2023 AACR Annual Meeting, noting that "proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our pre|CISION® technology to expand their use."
This asset has subsequently been absent from public pipeline disclosures — it does not appear in the current published pipeline. This could mean it was deprioritised, or it could mean it is being developed quietly as a future platform demonstration asset ahead of a future announcement. Proteasome inhibitors (like bortezomib/Velcade and carfilzomib/Kyprolis) are approved for multiple myeloma — primarily a non-solid tumour indication, where FAP expression is lower. However, pre|CISION® delivery into FAP-expressing solid tumour stroma could open proteasome inhibitors to a solid tumour application for the first time. The fact that this asset was presented publicly and then went quiet is a flag worth monitoring.
The year-end 2025 trading update explicitly states: "Intellectual property portfolio continued to grow and gain momentum measured by increased IP filings. These include two important advances in the pre|CISION® IP estate: the sustained release mechanism of payload delivery, piloted in the AVA6103 program; and the dual payload mechanism of delivery."
The key phrase is "continued to grow and gain momentum measured by increased IP filings." The company then names only two of the important advances — but uses language suggesting there are more they are not yet disclosing. New patent filings are secret for 18 months after filing under international convention, meaning filings from mid-2024 to present would not yet be visible in any public database. The Q1 2026 CEO statement that "the sustained release mechanism allows the modulation of the kinetics of payload release, and also opens up the platform to many therapeutic modalities over the Gen One approach" is the clearest hint yet that the platform architecture supports delivery modes not yet publicly discussed — including, potentially, non-IV routes. This was reinforced at Science Day 2026 where the CEO stated that Avacta is building IP "at a pace that we are confident exceeds industry norms" — language consistent with multiple undisclosed programmes in active development.
The May 6 2026 Science Day has now been held. None of the hidden platform signals (STING, oral delivery, AVA3996 proteasome inhibitor, radiopharmaceutical) were disclosed. However the CEO's explicit statement that IP pace "exceeds industry norms" is the strongest public confirmation yet that undisclosed programmes exist. The seven hidden signals in this section remain valid as forward-looking indicators — they have not been disproven, simply not yet confirmed.
The next highest-probability disclosure window for hidden platform signals is now: (1) any upcoming academic conference presentation; (2) the H2 2026 AVA6000 partnership announcement (where platform breadth often forms part of deal rationale); (3) year-end 2026 trading update. The IP that is "growing at a pace that exceeds industry norms" will eventually require public disclosure — either through a patent publication (18 months after filing) or a corporate announcement.
Two formal RNS announcements were released on the morning of Science Day confirming material new data across both AVA6103 and AVA6207. The pre-event RNS timing confirmed material new information rather than presentation summaries.
AVA6103 comparison extended from Enhertu to Datroway (datopotamab deruxtecan, TROP2-targeted, newly approved for NSCLC and breast cancer). AVA6103 outperforms both on TSI (≥3× higher vs either ADC) and Cmax (>1 log higher). The advantage is now confirmed across two different ADC targets (HER2 and TROP2) — proving the delivery superiority is target-agnostic, not model-specific. AZ/DSC now have two commercial products publicly outperformed by AVA6103 in the scientific record.
First time specific Tmax figures disclosed. AVA6103 reaches peak tumour concentration in minutes; Enhertu and Datroway take >24 hours. This is not incrementally faster — it is categorically different kinetics. A concentrated cytotoxic burst at the tumour site vs slow sustained ADC release. For rapidly dividing cancer cells, a high-intensity early peak is mechanistically superior to slow accumulation.
Updated in vivo data shows AVA6207 producing prolonged deep complete responses in models where tumours regrow with conventional cytotoxic drugs. In the FAP-low/HER2+ gastric PDX model, durable responses with AVA6207 observed where tumour regrowth occurs with Enhertu. In the FAP-high HEK-FAP model, deep complete responses where tumours regrow with conventional therapy. This is durability data, not just efficacy data — a clinically critical distinction.
The Enhertu and Datroway comparison data will be submitted to a peer-reviewed journal and presented at an upcoming academic meeting. This elevates the data permanently from "company claims" to "independently reviewed science" — the currency that pharma BD teams require for diligence.
"We continue to build momentum and enhance our IP — at a pace that we are confident exceeds industry norms." This is unusually bold public language. The STING patent, dual-payload Gen 3, AffDC, and accelerating IP filing rate all suggest this confidence is grounded. No new programme was disclosed today but the IP development velocity claim is itself a signal.
Against the five scenarios predicted in this section before the event:
Net assessment: Science Day delivered solid confirmatory and incremental data — the Datroway comparison and Tmax quantification are genuinely new. But it was not the transformative multi-announcement event the CEO's pre-event tone suggested. The partnership deal, royalty financing, and NASDAQ updates remain outstanding catalysts. The AVA6000 Phase 1b full data package is now confirmed for ASCO 2026. Abstract title already released — "activity against salivary gland cancers" is an efficacy signal. Full abstract: 21 May 2026. Presentation: 30 May–3 June Chicago. This is the next price-moving announcement.
Science Day confirmed the platform's technical superiority but held back the commercial catalysts. The outstanding events that still need to happen — and which will drive the next re-rating — are:
CEO Christina Coughlin's public statements in the days before Science Day contain unusually specific signals about the nature and scale of what is being disclosed. Reading them carefully against everything known about the platform, board composition, and strategic priorities produces a coherent picture:
"The next chapter" — not "an update" or "our latest data." Chapter implies a distinct new phase, a narrative step-change. CEOs do not use chapter language for routine clinical updates. This is deliberate framing for something categorically new.
Science Day delivered strong data but no partnership deal or new programme. The abstract title for ASCO 2026 — already published — is now the primary forward-looking catalyst for the investment thesis. The title decodes as a deliberate efficacy signal:
The Avacta board is not a collection of generic non-executives. When you map each member's specific background against Avacta's strategic objectives, a coherent and deliberate picture emerges — one that signals partnership deal execution, royalty financing, NASDAQ listing, and US commercial infrastructure as the near-term priorities. The board has been systematically assembled for the next phase, not the current one.
Who he is: CEO of Clinigen Group from 2012 IPO on AIM through to its £1.3bn sale to Triton Partners in April 2022. Clinigen was a global pharmaceutical services business operating in 100+ countries — its model was essentially providing access to medicines through licensing, commercialisation, and distribution partnerships. He oversaw multiple transformational acquisitions and was simultaneously NEC Chairman of C7Health (VC-backed medtech, acquired by strategic buyer 2022).
What he brings: The single most important credential on the board for where Avacta is going. Chilton has personally executed the AIM IPO → growth → strategic sale journey for a pharma company. He knows precisely what pharma partners look for in licensing negotiations, having been on the sell side at Clinigen. He also has a direct personal relationship with David Bryant — Bryant was part of the original Clinigen management team. That's not coincidental. The Clinigen alumni network on the Avacta board (Chilton + Bryant) is a deliberate structural signal.
Who she is: MD/PhD from University of Pennsylvania. Fellowship in Hematology and Oncology at Children's Hospital of Philadelphia. Translational research under Carl June (the godfather of CAR-T therapy) at UPenn. CMO at Immunocore where she led development of Kimmtrak (the first TCR-T therapy approved for uveal melanoma). CMO at Tmunity (autologous CAR-T/TCR-T). CMO at Rubius Therapeutics (allogeneic red cell therapy). CEO at CytoImmune Therapeutics. Pfizer Oncology Asset Team Leader. Novartis Clinical Program Lead.
What she brings: Four things almost no other AIM biotech CEO can match simultaneously: (1) operational CMO experience at two novel-mechanism approved drugs; (2) deep US oncology KOL relationships from her clinical career; (3) specific experience navigating FDA for novel platform drugs (Kimmtrak was a genuinely novel TCR-T bispecific); (4) named as In Vivo 2026 Rising Leader — one of 30 selected globally from across all of biopharma. That recognition is not honorary — it signals that the US institutional investor and pharma partnership community knows who she is.
Who he is: Medical oncologist and haematologist, faculty at Brigham and Women's Hospital and Harvard Medical School. Staff physician at Dana-Farber Cancer Institute (1996–2018). SVP Clinical Development at Genzyme (1996–2011) where he was responsible for multiple drug approvals including Mozobil, Fabrazyme, Aldurazyme. Executive management team at Synageva Biopharma (2011–2014, acquired by Alexion for $8.4bn). Current boards: GlycoMimetics, Blueprint Medicines, Idera Pharmaceuticals, Walden Biosciences. Previously: Audentes Therapeutics (acquired by Astellas for $3bn in 2020). American Cancer Society national board, Board Scientific Officer since 2022. 50+ published papers.
What he brings: Goldberg is the board's clinical and regulatory compass — and crucially, its US oncology institutional credibility. His simultaneous board seat at GlycoMimetics is where Brian Hahn just came from. That overlap is not accidental — it created a direct trust relationship between Goldberg and Hahn before Hahn joined Avacta. His Genzyme background covers rare and orphan disease development, directly relevant to the SGC orphan designation. His Synageva experience — a rare disease company sold for $8.4bn — is the precise outcome template for Avacta's SGC programme.
Who he is: 25+ years at GSK in senior finance roles including Head of Global Finance Services and CFO of GSK Italy. Director of Global Finance Operations at Vodafone. CFO of Immunocore (TCR-T biotherapeutics, the company behind Kimmtrak — the same drug Christina Coughlin shepherded to approval as CMO). CFO of Vectura Group (FTSE-listed inhaled drug delivery specialist). Now Audit Committee Chair at Avacta.
What he brings: The Immunocore overlap with Coughlin is highly significant. Fry was CFO and Coughlin was CMO at the same company — they have worked together in a senior capacity before joining Avacta. That pre-existing trust relationship explains the composition of the executive team. Fry brings specific knowledge of how to prepare a UK-listed, novel-platform biotech for the financial scrutiny required for a NASDAQ dual listing or a major partnership deal — he has done exactly this at Immunocore, which dual-listed on NASDAQ in 2021.
Who he is: 35+ years in pharma. Commercial leadership roles at GSK and Pfizer. One of the original management team at Clinigen Group from its 2012 AIM IPO through to its £1.3bn sale in 2022 — making him a direct Clinigen colleague of Shaun Chilton over a decade. Currently an active Advisor to Healthcare Royalty (HCRx) — the world's largest specialist biopharma royalty acquisition firm, now majority-owned by KKR, with $7bn+ deployed across 110+ products since inception.
What he brings: The most underappreciated appointment on the entire board. Bryant simultaneously occupies two strategic roles that are directly relevant to Avacta's most pressing needs: (1) a commercial pharma veteran who understands how big pharma BD teams evaluate licensing deals (from the GSK/Pfizer side of the table); and (2) an active HCRx advisor who represents Avacta's most direct channel into non-dilutive royalty financing. The Clinigen thread — Bryant and Chilton both being founding Clinigen management — gives the chairman and this NED a decade-long working relationship built on a shared success story. Companies do not appoint HCRx advisors to their boards without a financing conversation already in motion.
Who he is: Founder of Zeus Capital (2002), a London and Manchester-based boutique investment bank that floats approximately 30% of all AIM listings annually — raising ~£1bn/yr for growth companies. Previously served as managing director at Apax Partners. Co-founded boohoo.com and served as NED for 7 years through its 2014 AIM IPO (which Zeus handled). Acquired Crawford Healthcare for £700k in 2009, grew it to £30m+ revenue, sold to Acelity in 2018 for a reported ~£100m. Zeus Capital acted as sole bookrunner on Avacta's March 2026 £10m placing.
What he brings: Hughes is Avacta's capital markets infrastructure in human form. His appointment alongside his firm's role as bookrunner is a clear signal: Zeus Capital is being positioned as Avacta's long-term capital markets advisor, not just a transactional bookrunner. His Apax Partners background means he understands private equity deal structures — relevant if a PE-backed acquisition or take-private scenario emerges. His track record of building companies from small AIM listings to significant exits (Boohoo, Crawford Healthcare) mirrors precisely the journey Avacta is on.
Who he is: CFO of GlycoMimetics for 15 years, leading the company's 2014 NASDAQ IPO. Built GlycoMimetics' entire financial infrastructure from early stage through public company. Co-Chair of BIO's Finance and Tax Committee — the lobbying and policy body for 1,100+ biotech companies, for which he has testified before the US House Financial Services Committee on capital markets issues. Co-chair of the DC chapter of the Association for Bio Financial Officers. Former member of the SEC's Advisory Committee on Small and Emerging Companies. Shares the GlycoMimetics board seat with Mark Goldberg — they are colleagues from the same company.
What he brings: Hahn is explicitly built for one thing: NASDAQ. He has executed a NASDAQ IPO from within a clinical-stage biotech, knows the SEC requirements intimately (having served on their advisory committee), and sits at the centre of the US biotech finance community through his BIO committee co-chairmanship. His appointment in January 2025 — followed by the NASDAQ dual listing being cited as a corporate objective in the March 2026 deck — is not a coincidence. He was hired to execute a US capital markets strategy. His relationships with US biotech investors are direct and institutional, not introductory.
Read as a collective unit, the Avacta board tells a coherent and specific story about where the company is headed in the next 24–36 months:
The market is pricing Avacta as a pre-revenue clinical-stage company reliant on equity dilution. The board composition says it is a pre-revenue clinical-stage company with a fully assembled team capable of executing royalty financing, a NASDAQ listing, a pharma partnership deal, and a potential strategic exit — simultaneously. That is a materially different proposition.
Clinically validated platform priced as unproven concept — the discount to intrinsic value is structural, not speculative
There is an important distinction between a speculative investment — where you are betting that an unproven concept might work — and an undervalued investment, where you are buying a proven asset at a price that does not reflect what has already been demonstrated. Avacta sits firmly in the second category. The pre|CISION® delivery mechanism has been validated through direct human tumour biopsy: mean 860 ng/gm doxorubicin in tumour tissue vs 8.3 ng/ml in plasma — a 100–278:1 ratio measured directly in human cancer tissue, published in the Annals of Oncology. FAP expression level does not correlate with tumour drug concentration, confirming the mechanism works even in low-FAP tumours. The safety profile has been confirmed clinically — no maximum tolerated dose at 4× conventional doxorubicin dosing, with the FDA removing the lifetime cap entirely. The payloads are established cytotoxics with decades of data. And as of April 21 2026, AVA6103 has demonstrated activity even in very low FAP tumours, formally expanding the addressable population beyond the already-large FAP-high segment.
This is not a bet on whether the science works. The science works. This is a bet on whether the market re-rates a proven platform from its current ~£408M valuation toward the $3–12bn range that comparable validated drug conjugate platforms command in competitive acquisition scenarios. The risk is financial — dilution, partnership timing, cash runway — not scientific. And financial risk at this stage is considerably more manageable than the binary clinical risk that "speculative" implies. The 10-indication addressable market, the compounding de-risk curve across successive programmes, the ASCO data release on 21 May 2026, and the H2 2026 AVA6103 Phase 1 clinical data all represent near-term catalysts that could close the gap between current price and intrinsic value. At 89p versus a base-case rNPV of 150–300p and a competitive acquisition floor of 250–380p, the current price represents an anomalous discount to a platform whose core scientific proposition is no longer in question. The stock has broken through the 75p convertible bond ceiling and the 84.5p 52-week high — the technical and fundamental cases are now aligned.
⚠️ IMPORTANT DISCLAIMER: This report is for informational and research purposes only. It does not constitute financial advice and should not be used as the sole basis for any investment decision. Clinical-stage biotech investments carry a high risk of loss, including total loss of capital. Clinical trial outcomes are binary and unpredictable. Past share price performance is not a reliable indicator of future results. The convertible bond, cash burn rate, and funding requirements mean the company may need to raise further equity on terms dilutive to existing shareholders. Always conduct your own research and consider consulting an authorised financial adviser before making investment decisions. Nothing in this report constitutes a personal recommendation to buy or sell any security. Report reflects data as of 13 May 2026, share price 89p. I am an AI assistant, not a licensed financial professional.